MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$3,543,203
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from sale of common sto...
Depreciation
Stock-based compensation
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued exp...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,587,954
-4,937,046
-5,955,802
-3,218,481
Stock-based compensation
2,445
2,555
85,068
18,452
Common stock issued for license agreement
-
-
0
0
Depreciation
11,132
1,868
1,020
697
Loss (gain) on disposal of fixed assets
-
-
-2,559
0
Prepaid expenses and other current assets
353,210
293,790
-961,819
-401,661
Deferred offering costs
-
-
-
43,700
Accounts payable and accrued expenses
-611,795
577,795
1,809,866
667,201
Net cash used in operating activities
-3,539,382
-4,648,618
-3,051,770
-2,174,170
Purchase of property and equipment
3,821
6,179
18,175
-
Net cash used in investing activities
-3,821
-6,179
-18,175
-
Payments of deferred offering costs
46,000
-
64,082
0
Payments on notes payable
90,782
96,218
30,791
90,974
Proceeds from exercises, including future exercises, of warrants
7,000
-
0
844
Payments to stockholders for stock split rounding
0
0
0
1,486
Proceeds from subscription receivable
0
0
0
0
Proceeds from sale of common stock
-
-
501,745
0
Proceeds from equity issuance
-
500,878
-
-
Proceeds from sale of common stock and pre-funded warrants, net
21,208,000
-
-
-
Net cash provided by financing activities
20,577,340
404,660
406,872
-91,616
Net change in cash and cash equivalents
17,034,137
-4,250,137
-2,663,073
-2,265,786
Cash and cash equivalents, at beginning of period
2,950,877
7,201,014
9,864,087
6,461,378
Cash and cash equivalents, at end of period
19,985,000
2,950,877
7,201,014
9,864,087
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common stock and...
$21,208,000
Net cash provided by
financing activities
$20,577,340
(44.37%↑ Y/Y)
Canceled cashflow
$136,782
Net change in cash
and cash...
$17,034,137
(200.51%↑ Y/Y)
Canceled cashflow
$3,543,203
Payments on notes payable
$90,782
(-48.36%↓ Y/Y)
Payments of deferred
offering costs
$46,000
Depreciation
$11,132
(405.77%↑ Y/Y)
Stock-based compensation
$2,445
(-97.10%↓ Y/Y)
Net cash used in
operating activities
-$3,539,382
(58.77%↑ Y/Y)
Net cash used in
investing activities
-$3,821
Canceled cashflow
$13,577
Net loss
-$2,587,954
(61.24%↑ Y/Y)
Accounts payable and
accrued expenses
-$611,795
(34.54%↑ Y/Y)
Prepaid expenses and
other current assets
$353,210
(-66.70%↓ Y/Y)
Purchase of property and
equipment
$3,821
Buy us a coffee
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)